IL316075A - Crystalline form of lenifranor - Google Patents

Crystalline form of lenifranor

Info

Publication number
IL316075A
IL316075A IL316075A IL31607524A IL316075A IL 316075 A IL316075 A IL 316075A IL 316075 A IL316075 A IL 316075A IL 31607524 A IL31607524 A IL 31607524A IL 316075 A IL316075 A IL 316075A
Authority
IL
Israel
Prior art keywords
lanifibranor
crystalline form
crystalline
Prior art date
Application number
IL316075A
Other languages
English (en)
Hebrew (he)
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of IL316075A publication Critical patent/IL316075A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL316075A 2022-04-05 2023-04-04 Crystalline form of lenifranor IL316075A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22305456 2022-04-05
PCT/EP2023/058743 WO2023194339A1 (en) 2022-04-05 2023-04-04 Crystalline form of lanifibranor

Publications (1)

Publication Number Publication Date
IL316075A true IL316075A (en) 2024-12-01

Family

ID=81326293

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316075A IL316075A (en) 2022-04-05 2023-04-04 Crystalline form of lenifranor

Country Status (14)

Country Link
US (1) US20250243192A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504725A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511847A (cg-RX-API-DMAC7.html)
KR (1) KR20250002337A (cg-RX-API-DMAC7.html)
CN (1) CN119301120A (cg-RX-API-DMAC7.html)
AR (1) AR128985A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023250118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247273A1 (cg-RX-API-DMAC7.html)
IL (1) IL316075A (cg-RX-API-DMAC7.html)
MX (1) MX2024012348A (cg-RX-API-DMAC7.html)
PY (1) PY2324870A (cg-RX-API-DMAC7.html)
TW (1) TW202404966A (cg-RX-API-DMAC7.html)
UY (1) UY40216A (cg-RX-API-DMAC7.html)
WO (1) WO2023194339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022325334A1 (en) * 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof
JP2026501899A (ja) 2023-01-19 2026-01-16 インベンティバ ラニフィブラノール製剤
WO2024251730A1 (en) 2023-06-05 2024-12-12 Inventiva Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition
AR133887A1 (es) * 2023-09-22 2025-11-12 Inventiva Método de fabricación de lanifibranor
IL330214A (en) 2023-12-21 2026-08-01 Inventiva Combination therapy for the prevention and/or treatment of liver disease
AU2024409290A1 (en) 2023-12-21 2026-08-06 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
WO2025191117A1 (en) 2024-03-15 2025-09-18 Inventiva Prevention of blood disorders in patient treated with a ppar agonist
TW202604485A (zh) 2024-05-17 2026-02-01 法商因文帝華公司 患有肝損傷患者肝疾病之治療
WO2026115290A1 (en) 2024-11-28 2026-06-04 Inventiva Non-invasive monitoring of nash treatment with lanifibranor
WO2026125286A1 (en) 2024-12-09 2026-06-18 Inventiva Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in the treatment of liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022143479A1 (zh) 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
US20240246949A1 (en) 2021-06-10 2024-07-25 Teva Pharmaceuticals International Gmbh Solid state forms of lanifibranor and process for preparation thereof
CN115466252A (zh) 2021-06-11 2022-12-13 上海希迈医药科技有限公司 一种Lanifibranor的晶型及其制备方法
AU2022325334A1 (en) 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
MX2024012348A (es) 2024-11-08
JP2025511847A (ja) 2025-04-16
EP4504725A1 (en) 2025-02-12
WO2023194339A1 (en) 2023-10-12
TW202404966A (zh) 2024-02-01
UY40216A (es) 2023-10-31
CA3247273A1 (en) 2023-10-12
PY2324870A (es) 2023-10-27
CN119301120A (zh) 2025-01-10
US20250243192A1 (en) 2025-07-31
KR20250002337A (ko) 2025-01-07
AR128985A1 (es) 2024-07-03
AU2023250118A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
IL315411A (en) Pure forms of crystalline eticarpant
LT4313945T (lt) Kristalinė 5-meo-dmt hidrobromido druska
PL4508919T3 (pl) Konfiguracja wielu wartości wyprzedzenia czasowego
GB202102360D0 (en) Crystalline compound
IL325727A (en) Crystalline form
GB202204778D0 (en) Novel crystalline salt forms of mesembrine
GB202411655D0 (en) Application of circHIF1a
AU2024314489A1 (en) Crystalline salts of linsitinib
IL321171A (en) Crystalline forms of 2-oxoquinazoline
IL326152A (en) Solid state forms of GUSACITINIB
SMT202600195T1 (it) Forme cristalline di evenamide
GB202014196D0 (en) Crystalline form III of tetraacetylethylenediamine
IL304683A (en) Crystalline form of a piperazinyl-thiazole derivative
GB202009218D0 (en) Crystalline forms of entrectinib
GB202002054D0 (en) Crystalline forms of entrectinib
GB201912411D0 (en) Crystalline forms of ivosidenib
HK40116601A (en) Crystalline form of lanifibranor
EP4121434A4 (en) CRYSTALLINE FORMS OF SQUALAMINE
HK40096047A (en) Crystalline form of aspacytarabine
HK40082031A (en) Crystalline form of lnp023
HK40111295A (en) Crystalline forms of trofinetide
AU2024361448A1 (en) Crystalline forms of mrtx0902
CA3288524A1 (en) Crystalline forms of evenamide
GB202314050D0 (en) Novel form of bemcentinib
GB202316444D0 (en) Salts of opicapone